摘要
目的:观察诺和锐30与诺和灵30R对病程不超过4年的2型糖尿病(T2DM)患者的血糖控制的疗效比较。方法:选择T2DM患者88例,随机分为应用诺和锐30与诺和灵30R组,每日早晚餐前即刻注射诺和锐30或餐前30min注射诺和灵30R,起始剂量为0.4U/(kg·d),联合午餐后二甲双胍0.5g治疗12周。结果:诺和锐30组患者中晚餐前血糖、餐后2h血糖、HbA1c、改善B细胞功能、降低胰岛素抵抗方面优于诺和灵30R组(P<0.05),且达标时间短,低血糖发生率低,但胰岛素用量略高于诺和灵30R组。结论:对疗程较短的T2DM患者注射诺和锐30联合午餐后二甲双胍口服方案能更好地控制血糖,改善B细胞功能,降低胰岛素抵抗。
Objective：To compare the glycemic control efficacy of Novorapid 30 and Novolin 30R in the treatment of type 2 diabetes patients with disease duration of less than 4 years.Methods：88 cases of patients with T2DM were randomly assigned to Novorapid 30 and Novolin 30R group.The patients were either given Novorapid 30 right before breakfast and dinner or given Novolin 30R 30 minutes before meals.The starting dose was 0.4 U/（kg·d） and combined treatment with Melbine 0.5 g after lunch lasted for 12 weeks.Results：Blood glucose before dinner,2-hour postprandial blood glucose,HbA1c,B cell function improvement,insulin resistance reduction of Novorapid 30 group were better than the Novolin 30R group（P〈0.05）.The time to achieve standard level was also shorter in the Novorapid 30 group and incidence of hypoglycemia was lower in this group.However,using of insulin was slightly higher in this group.Conclusion：Novorapid 30 injection combined with Melbine oral intake after lunch in patients with short course T2DM has better blood glucose control results,improves B cell function and reduces insulin resistance.
出处
《中国当代医药》
2011年第28期46-47,共2页
China Modern Medicine
